Drug class profile · refreshed daily from federal data

Nonsteroidal Mineralocorticoid-Receptor Antagonist

1 molecule in this class, $651.2M combined CY2024 Part D spend across 667K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Nonsteroidal Mineralocorticoid-Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $651.2Mcombined across class
Total Rx claims: 667K176K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Finerenone

Brand: Kerendia · 667K Part D claims (CY24) · 176K beneficiaries · First FDA approval: 2021-07-09

Brand-only (no generics) 735 plans require PA

Low NADAC$22.85

→

Avg plan cost$22.86

Part D spend $651.2M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.